JP2017531648A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531648A5
JP2017531648A5 JP2017518131A JP2017518131A JP2017531648A5 JP 2017531648 A5 JP2017531648 A5 JP 2017531648A5 JP 2017518131 A JP2017518131 A JP 2017518131A JP 2017518131 A JP2017518131 A JP 2017518131A JP 2017531648 A5 JP2017531648 A5 JP 2017531648A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
hydrogen
compound according
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531648A (ja
JP6629847B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/072868 external-priority patent/WO2016050975A1/en
Publication of JP2017531648A publication Critical patent/JP2017531648A/ja
Publication of JP2017531648A5 publication Critical patent/JP2017531648A5/ja
Application granted granted Critical
Publication of JP6629847B2 publication Critical patent/JP6629847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518131A 2014-10-03 2015-10-02 縮合五員環イミダゾール誘導体 Active JP6629847B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP14290299.8 2014-10-03
EP14290299 2014-10-03
EP15162641.3 2015-04-07
EP15162641 2015-04-07
EP15171036.5 2015-06-08
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en) 2014-10-03 2015-10-02 Fused pentacyclic imidazole derivatives

Publications (3)

Publication Number Publication Date
JP2017531648A JP2017531648A (ja) 2017-10-26
JP2017531648A5 true JP2017531648A5 (cg-RX-API-DMAC7.html) 2018-11-08
JP6629847B2 JP6629847B2 (ja) 2020-01-15

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518131A Active JP6629847B2 (ja) 2014-10-03 2015-10-02 縮合五員環イミダゾール誘導体

Country Status (36)

Country Link
US (3) US10202405B2 (cg-RX-API-DMAC7.html)
EP (1) EP3201196B1 (cg-RX-API-DMAC7.html)
JP (1) JP6629847B2 (cg-RX-API-DMAC7.html)
KR (1) KR102442235B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108672B (cg-RX-API-DMAC7.html)
AP (1) AP2017009809A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015326798B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017006669B1 (cg-RX-API-DMAC7.html)
CA (1) CA2962826C (cg-RX-API-DMAC7.html)
CL (1) CL2017000787A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003331A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170167A (cg-RX-API-DMAC7.html)
DK (1) DK3201196T3 (cg-RX-API-DMAC7.html)
EA (1) EA032839B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17027306A (cg-RX-API-DMAC7.html)
ES (1) ES2885432T3 (cg-RX-API-DMAC7.html)
GT (1) GT201700044A (cg-RX-API-DMAC7.html)
HR (1) HRP20211605T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056133T2 (cg-RX-API-DMAC7.html)
IL (1) IL251147B (cg-RX-API-DMAC7.html)
LT (1) LT3201196T (cg-RX-API-DMAC7.html)
MA (1) MA40770B1 (cg-RX-API-DMAC7.html)
MX (1) MX380578B (cg-RX-API-DMAC7.html)
MY (1) MY181019A (cg-RX-API-DMAC7.html)
PE (1) PE20170693A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500414B1 (cg-RX-API-DMAC7.html)
PL (1) PL3201196T3 (cg-RX-API-DMAC7.html)
RS (1) RS62423B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701796XA (cg-RX-API-DMAC7.html)
SI (1) SI3201196T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000083A1 (cg-RX-API-DMAC7.html)
TW (1) TWI719949B (cg-RX-API-DMAC7.html)
UA (1) UA120764C2 (cg-RX-API-DMAC7.html)
UY (1) UY36341A (cg-RX-API-DMAC7.html)
WO (1) WO2016050975A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701946B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000083A1 (en) * 2014-10-03 2018-07-04 Sanofi Sa Fused pentacyclic imidazole derivatives
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3436459B1 (en) 2016-04-01 2021-08-25 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
EA201892142A1 (ru) * 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
US10793578B2 (en) 2016-04-01 2020-10-06 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
EP3436456B1 (en) * 2016-04-01 2021-11-17 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of tnf activity
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
JP7121033B2 (ja) * 2017-03-15 2022-08-17 ユーシービー バイオファルマ エスアールエル Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
MA49055B1 (fr) * 2017-04-25 2021-12-31 Sanofi Sa Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
WO2020084008A1 (en) 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
EP4622981A1 (en) * 2022-11-23 2025-10-01 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) * 2023-01-05 2024-07-11 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
AU2024264495A1 (en) 2023-04-26 2025-12-11 Sanofi Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
WO2024251282A1 (zh) * 2023-06-09 2024-12-12 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
CN119630670A (zh) * 2023-08-16 2025-03-14 瑞雷拉公司 TNFα活性调节剂及其用途
TW202527952A (zh) 2023-09-29 2025-07-16 法商賽諾菲公司 合成方法
WO2025137267A1 (en) * 2023-12-21 2025-06-26 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025212627A1 (en) * 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025244936A1 (en) * 2024-05-20 2025-11-27 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
CA2517281A1 (en) 2003-03-10 2004-10-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
KR101941420B1 (ko) 2011-06-20 2019-01-23 스페로 트리넴, 인코포레이티드 자이라제 및 토포이소머라제 억제제의 인산에스테르
ES2675583T3 (es) * 2012-06-11 2018-07-11 Ucb Biopharma Sprl Bencimidazoles moduladores de TNF-alfa
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
TN2017000083A1 (en) * 2014-10-03 2018-07-04 Sanofi Sa Fused pentacyclic imidazole derivatives

Similar Documents

Publication Publication Date Title
JP2017531648A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019512535A5 (cg-RX-API-DMAC7.html)
RU2016127623A (ru) Производные бензотриазола в качестве модуляторов активности tnf
RU2016126974A (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
JP2015511638A5 (cg-RX-API-DMAC7.html)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
JP2017532360A5 (cg-RX-API-DMAC7.html)
RU2016126970A (ru) Производные имидазопиридазина в качестве модуляторов активности tnf
RU2016127621A (ru) Производные имидазопиридина в качестве модуляторов активности tnf
JP2016522232A5 (cg-RX-API-DMAC7.html)
RU2341527C1 (ru) Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
CY1116231T1 (el) ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ
RU2016127228A (ru) Производные триазолопиридина в качестве модуляторов активности tnf
JP2014521653A5 (cg-RX-API-DMAC7.html)
JP2016040288A5 (cg-RX-API-DMAC7.html)
JP2017510663A (ja) Mertk特異的ピリミジン化合物
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
RU2016127227A (ru) Производные имидазопиридина в качестве модуляторов активности tnf
RU2016126968A (ru) Производные имидазотриазина в качестве модуляторов активности tnf
RU2015124381A (ru) Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона
JP2015501833A5 (cg-RX-API-DMAC7.html)
RU2015116749A (ru) Антагонисты mglu2/3 для лечения аутических расстройств
EA201991025A1 (ru) Липосомальный препарат для применения для лечения злокачественного новообразования